Your session is about to expire
← Back to Search
Medication Reduction Program for Overmedication
N/A
Recruiting
Research Sponsored by McMaster University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Aged 70 years of age or older
Currently taking 5 or more long-term medications
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 week, 3 month, 6 month
Awards & highlights
Study Summary
This trial tests a program to reduce the amount of medications seniors take. The program uses patient preferences and a pharmacist to decide which medications to stop or reduce. It also monitors patient health outcomes.
Who is the study for?
This trial is for seniors aged 70 or older who are taking five or more long-term medications and have not had a recent comprehensive medication review. They must be willing to try discontinuing some medications, have a family doctor involved in their care, and be able to understand and respond to rating scales. Those with terminal illness or inadequate English language/cognitive skills are excluded.Check my eligibility
What is being tested?
The study tests the TAPER program's effectiveness on reducing the number of medications and improving health outcomes for seniors dealing with polypharmacy. It involves patient interviews, pharmacist-led medication reviews, dose reduction strategies, electronic monitoring tools for side effects, and follow-ups with doctors.See study design
What are the potential side effects?
While this trial focuses on reducing medication intake which may decrease potential drug side effects overall, specific risks associated with adjusting current prescriptions will vary based on individual patient conditions and the particular drugs being reduced.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 70 years old or older.
Select...
I am on 5 or more long-term medications.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 week, 3 month, 6 month
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 week, 3 month, 6 month
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Feasibility (recruitment number)
Secondary outcome measures
Feasibility (barriers to recruitment)
Feasibility (capacity for pharmacist to implement)
Feasibility (intervention implementation proportion)
+6 moreOther outcome measures
Changes in medication side effects and symptoms (adverse)
Pharmaceutical Preparations
Falls
+22 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: TAPERExperimental Treatment1 Intervention
The intervention is medication reduction. This arm is comprised of:
Medication reconciliation
Identification of patient priorities for care
Identification of medications that are potentially appropriate for discontinuation/dose reduction
Linked pharmacist/family physician consultations with patient to discuss medication with intention to reduce
Identification of medications for trial of discontinuation/dose reduction (shared decision making)
Pause of medication and clinical monitoring
Find a Location
Who is running the clinical trial?
McMaster UniversityLead Sponsor
881 Previous Clinical Trials
2,597,856 Total Patients Enrolled
Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,344 Previous Clinical Trials
26,453,387 Total Patients Enrolled
David Braley and Nancy Gordon Chair in Family MedicineOTHER
3 Previous Clinical Trials
1,006 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have a severe illness that makes it impossible for you to participate in the study for a minimum of 6 months.I am willing to stop my current treatment.You do not understand the rating scales or have difficulty responding to them due to language or cognitive limitations.I am 70 years old or older.I am on 5 or more long-term medications.
Research Study Groups:
This trial has the following groups:- Group 1: TAPER
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is the current enrollment of this clinical trial?
"Affirmative. Clinicaltrials.gov outlines that this clinical trial is currently recruiting participants. This investigation, which was posted on June 16th 2019 and modified March 14th 2023, requires 30 individuals to be recruited from a single site."
Answered by AI
Is the experiment still enrolling participants?
"Affirmative. According to clinicaltrials.gov, the trial is currently accepting participants and was first posted on June 16th 2019. The study has most recently been updated on March 14th 2023 and seeks to enrol 30 patients at a single site."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger